AndrewJohnArmstrongMDScM, FACP

Genitourinary Oncology, Hematologic Oncology

Professor of Medicine, Surgery, Pharmacology and Cancer Biology. Director of Research, Duke Cancer Institute’s Center for Prostate and Urologic Cancers, Member of the Duke Cancer Institute

Join to view full profile

Dr. Armstrong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Armstrong's full profile

Already have an account?

Office
20 Duke Medicine Cir
Durham, NC 27710
Phone+1 888-275-3853

Fax+1 919-613-3900
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2000 - 2003
University of Virginia School of MedicineClass of 2000

Certifications & Licensure

NC State Medical License 2006 - 2025
MD State Medical License 2003 - 2006
PA State Medical License 2001 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Alpha Omega Alpha member AOA

Clinical Trials

Multimodality Phase II Study in Prostate Cancer Start of enrollment: 2008 Dec 01
Terminated
Phase 2
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer Start of enrollment: 2009 Jul 01
Terminated
Phase 2
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Sep 01
Completed
Phase 2
Pazopanib, Docetaxel, Prednisone Prostate Start of enrollment: 2011 Jun 01
Completed
Phase 1
BKM120 in Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2011 Aug 01
Terminated
Phase 2
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1
Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology Start of enrollment: 2012 May 01
Withdrawn
Not Applicable
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) Start of enrollment: 2014 Apr 01
Completed
Phase 2
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) Start of enrollment: 2014 Mar 01
Completed
Not Applicable
Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2015 May 06
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
Fred Saad, Andrew J Armstrong, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu, Craig Gedye, Gary L Buchschacher Jr, Ji Youl Lee, Urban Emmenegger, Jiri Navratil, Juan...> ;European Urology Oncology. 2024 Apr 5
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
Matthew P Deek, Philip Sutera, Yuezhou Jing, Robert Gao, Emily Rothman, Heather Day, David Chang, Piet Dirix, Andrew J Armstrong, Bethany Campbell, Fernando Lopez Camp...> ;European Urology Oncology. 2024 Apr 2
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
Joseph J Park, Alec Chu, Jinju Li, Alicia Ali, Rana R McKay, Clara Hwang, Matthew K Labriola, Albert Jang, Deepak Kilari, George Mo, Deepak Ravindranathan, Laura S Gra...> ;JCO Precision Oncology. 2024 Apr 1
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Park, J., Susan Halabi, Siyuan Guo, Joseph J Park, David M Nanus, Daniel J George, Emmanuel S Antonarakis, Daniel Costin Danila, Russell Zelig Szmulewitz, Donald P McD...> ;Clinical Cancer Research. 2024 Mar 15
Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.
Wang, J., Wong, T., Wu, K., Mullikin, T., Armstrong, A.> ;BMJ Case Reports. 2024 Feb 23
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.
Koontz, B., Halabi, S., Howard, L., Anand, M., George, D., Lee, W., Fecteau, R., Hoffman, K., Zhang, T., Berry, W., Harrison, M., Corn, P., Armstrong, A.> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 22
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with ...
Andrew B Nixon, Yingmiao Liu, Qian Yang, Bin Luo, Mark D Starr, John C Brady, Wm Kevin Kelly, Himisha Beltran, Michael J Morris, Daniel J George, Andrew J Armstrong, S...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 12
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong, A., Geva, R., Chung, H., Lemech, C., Miller, W., Hansen, A., Lee, J., Tsai, F., Solomon, B., Kim, T., Rolfo, C., Giranda, V., Ren, Y., Liu, F., Kandala, B.,...> ;Investigational New Drugs. 2024 Feb 1
2 citations
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly, W., Danila, D., Lin, C., Lee, J., Matsubara, N., Ward, P., Armstrong, A., Pook, D., Kim, M., Dorff, T., Fischer, S., Lin, Y., Horvath, L., Sumey, C., Yang, Z., ...> ;Cancer Discovery. 2024 Jan 12
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Gomez-Veiga, F., Azad, A., Iguchi, T., Villers, A., Alcaraz, A., Alekseev, B., Rosbrook, B., Zohren, F., Ma, J., Haas, G., Stenzl, A., Szmulewitz, R., Holzbeierlein, J...> ;European Urology Oncology. 2023 Dec 9
13 citations
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a...
Fred Saad, Noel W Clarke, Mototsugu Oya, Neal Shore, Giuseppe Procopio, João Daniel Guedes, Cagatay Arslan, Niven Mehra, Francis Parnis, Emma Brown, Friederike Schlürm...> ;The Lancet. Oncology. 2023 Oct 1
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Park, J., Holland, B., Jang, A., Clara Hwang, Nicholas C Henderson, Shih-Chun Chu, Brandon Holland, Frank C Cackowski, Amanda Pilling, Albert Jang, Shoshana Rothstein,...> ;JAMA Network Open. 2023 Sep 5
Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer.
Spratt, D., Tang, S., Sun, Y., Huang, H., Chen, E., Mohamad, O., Armstrong, A., Tward, J., Nguyen, P., Lang, J., Zhang, J., Mitani, A., Simko, J., DeVries, S., van der...> ;NEJM Evidence. 2023 Aug 1
Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correla...
Rhonda L Bitting, Yuan Wu, Jason A Somarelli, James A Proudfoot, Yang Liu, Elai Davicioni, Daniel J George, Andrew J Armstrong> ;JCO Precision Oncology. 2023 Aug 1
Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur U...
Luke C Ardolino, Rachel Dear, Andrew J Armstrong, Silke Gillessen, Anthony M Joshua> ;European Urology. 2023 Oct 1
Predictive biomarkers in advanced prostate cancer.
Andrew J Armstrong> ;Clinical Advances in Hematology & Oncology. 2023 Jun 1
Reply to E. Hindié.
Hannah D McManus, Andrew J Armstrong> ;Journal of Clinical Oncology. 2023 Aug 1
3 citations
Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.
Hannah D McManus, Dylan Zhang, Fides R Schwartz, Yuan Wu, Jordan Infield, Ethan Ho, Andrew J Armstrong, Daniel J George, Rajan T Gupta, Michael R Harrison, Danielle Kruse> ;Clinical Genitourinary Cancer. 2023 Dec 1
2 citations
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Andrew J Armstrong, Taro Iguchi, Arun A Azad, Arnauld Villers, Boris Alekseev, Daniel P Petrylak, Russell Z Szmulewitz, Antonio Alcaraz, Neal D Shore, Jeffrey Holzbeie...> ;European Urology. 2023 Aug 1
24 citations
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conferenc...
Sharifi, N., Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Nicholas D James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christ...> ;European Journal of Cancer. 2023 May 1
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C Araujo, Christopher Logothetis, Cora N Sternberg, Andrew J Armstrong, Michael A Carducci, Kim N Chi, Johann S de Bo...> ;Journal of Clinical Oncology. 2023 May 20
3 citations
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Michael J Morris, Glenn Heller, David W Hillman, Olivia Bobek, Charles Ryan, Emmanuel S Antonarakis, Alan H Bryce, Olwen Hahn, Himisha Beltran, Andrew J Armstrong, Law...> ;Journal of Clinical Oncology. 2023 Jun 20
The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.
Hannah D McManus, Andrew J Armstrong> ;Journal of Clinical Oncology. 2023 Jul 10
8 citations
RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis.
Mu-En Wang, Jiaqi Chen, Yi Lu, Alyssa R Bawcom, Jinjin Wu, Jianhong Ou, John M Asara, Andrew J Armstrong, Qianben Wang, Lei Li, Yuzhuo Wang, Jiaoti Huang, Ming Chen> ;The Journal of Clinical Investigation. 2023 May 15
3 citations
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J George, David M Nanus, Emmanuel S Antonarakis, Daniel C Danila, Russell Z Szmulew...> ;Clinical Cancer Research. 2023 May 15
Join now to see all

Lectures

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
2019 ASCO Annual Meeting - 6/1/2019
The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treat...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Closing in on New Treatments for Prostate CancerFebruary 17th, 2023
Prostate Cancer CTC PSMA Status Could Guide TherapyOctober 3rd, 2022
What Is Kidney Cancer? Symptoms, Causes, Diagnosis, Treatment, and PreventionJune 12th, 2022
Join now to see all